Brokers Set Expectations for Allogene Therapeutics Inc’s Q1 2019 Earnings (ALLO)

Share on StockTwits

Allogene Therapeutics Inc (NASDAQ:ALLO) – Analysts at Jefferies Financial Group issued their Q1 2019 earnings estimates for shares of Allogene Therapeutics in a research note issued on Monday, March 11th. Jefferies Financial Group analyst B. Amin forecasts that the company will post earnings of ($0.39) per share for the quarter. Jefferies Financial Group also issued estimates for Allogene Therapeutics’ Q2 2019 earnings at ($0.50) EPS, Q3 2019 earnings at ($0.54) EPS, Q4 2019 earnings at ($0.61) EPS, FY2019 earnings at ($2.04) EPS, FY2020 earnings at ($2.28) EPS, FY2021 earnings at ($2.59) EPS, FY2022 earnings at ($3.02) EPS and FY2023 earnings at ($2.51) EPS.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Friday, March 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.10).

Other equities research analysts have also recently issued reports about the company. Raymond James initiated coverage on Allogene Therapeutics in a research note on Thursday. They issued an “outperform” rating and a $40.00 target price on the stock. William Blair initiated coverage on Allogene Therapeutics in a research note on Wednesday. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $29.00 target price on shares of Allogene Therapeutics in a research note on Monday, March 11th. Cowen reiterated a “buy” rating on shares of Allogene Therapeutics in a research note on Friday, March 8th. Finally, Zacks Investment Research cut Allogene Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 28th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Allogene Therapeutics has a consensus rating of “Buy” and an average price target of $34.20.

Shares of ALLO opened at $26.74 on Thursday. Allogene Therapeutics has a 12-month low of $21.67 and a 12-month high of $35.55. The firm has a market cap of $3.22 billion and a P/E ratio of -4.06.

Hedge funds have recently bought and sold shares of the business. Strs Ohio bought a new stake in Allogene Therapeutics in the fourth quarter valued at $156,000. Creative Planning bought a new stake in Allogene Therapeutics in the fourth quarter valued at $544,000. VV Manager LLC bought a new stake in Allogene Therapeutics in the fourth quarter valued at $206,853,000. Artal Group S.A. bought a new stake in Allogene Therapeutics in the fourth quarter valued at $10,772,000. Finally, Shikiar Asset Management Inc. bought a new stake in Allogene Therapeutics in the fourth quarter valued at $1,056,000. Institutional investors own 44.94% of the company’s stock.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent.

Featured Story: Marijuana Stocks Investing Considerations

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Avedro Inc  to Post Q1 2019 Earnings of  Per Share, Svb Leerink Forecasts
Avedro Inc to Post Q1 2019 Earnings of Per Share, Svb Leerink Forecasts
Altaba  Cut to “Hold” at BidaskClub
Altaba Cut to “Hold” at BidaskClub
BidaskClub Upgrades Green Brick Partners  to Buy
BidaskClub Upgrades Green Brick Partners to Buy
BidaskClub Lowers Baozun  to Hold
BidaskClub Lowers Baozun to Hold
Brokers Set Expectations for Allogene Therapeutics Inc’s Q1 2019 Earnings
Brokers Set Expectations for Allogene Therapeutics Inc’s Q1 2019 Earnings
Dicks Sporting Goods Inc  Expected to Earn Q1 2020 Earnings of $0.64 Per Share
Dicks Sporting Goods Inc Expected to Earn Q1 2020 Earnings of $0.64 Per Share


Leave a Reply

© 2006-2019 Ticker Report